SCHEMBL7416443

SCHEMBL7416443

CCOc1ccc(S(=O)(=O)c2ccccc2)cc1CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.47
MMP12 P39900 6/20 0.47
MMP13 P45452 6/20 0.47
MMP14 P50281 6/20 0.47
MMP8 P22894 4/20 0.47
MMP16 P51512 4/20 0.47
SQSTM1 Q13501 1/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
MMP9 P14780 5/20 0.45
MMP1 P03956 4/20 0.45
MMP3 P08254 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
GLA P06280 1/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.44
APEX1 P27695 1/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7417562 0.83 TP53 (0.42) L3MBTL1PTGDR2LMNAMAPK1RAB9A
SCHEMBL8058697 0.79 HTR6 (0.46) L3MBTL1LMNAMAPK1RAB9AALDH1A1
SCHEMBL7414743 0.79 HTT (0.53) PTGDR2LMNAALDH1A1
SCHEMBL1628791 0.76 L3MBTL1 (0.62) L3MBTL1GLAALDH1A1
Hydrochloric Acid SCHEMBL2525349 0.75 L3MBTL1 (0.61) L3MBTL1GLAALDH1A1
SCHEMBL23229170 0.74 HSD17B10 (0.51) L3MBTL1GLAPTGDR2MAPK1HSD17B10
SCHEMBL17967503 0.73 HSD17B10 (0.77) LMNAMAPK1HSD17B10
SCHEMBL20847652 0.71 MEN1 (0.66) SQSTM1KEAP1NFE2L2L3MBTL1MAPK1
SCHEMBL1982527 0.71 APEX1 (0.52) L3MBTL1APEX1LMNAALDH1A1
SCHEMBL9899219 0.70 GLA (0.46) L3MBTL1GLALMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1163214-A1 GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 Merck Frosst Canada & Co. (CA) 2001-12-19 EP disclosed
US-6225288-B1 IMPLICATED IN MODULATING APOPTOSIS; TREATMENT OF:CARDIAC AND CEREBRAL ISCHEMIA/REPERFUSION INJURY, SPINAL CORD INJURY AND ORGAN DAMAGE DURING TRANSPLANTATION, CHRONIC NEURODEGENERATIVE DISEASES, IMMUNODEFICIENCY, DIABETES, ALOPECIA, AGING MERK FROSST CANADA & CO. (CA) 2001-05-01 US disclosed
WO-2000055127-A1 GAMMA-KETOACID DIPEPTIDES AS INHIBITORS OF CASPASE-3 MERCK FROSST CANADA & CO. (CA) 2000-09-21 WO disclosed